The pro-inflammatory enzyme COX-2 is known as one of many NF-κB dependent gene end products that is involved in the most inflammatory processes and, therefore represents a major target of many classic anti-inflammatory drugs (107), further underlining the great potential of Calebin A in cancer therapy. This evidence concerns the gene NFKB1 and cancer.